Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis

Abstract

European Medicines Agency EudraCT-Nr. 2015-001618-83 and 2016-000493-38.